



Symptom Control During Chemotherapy (SCDC)

MN Community Measurement



MN Community Measurement


- Nonprofit health care quality improvement and reporting organization
- Specialize in developing, collecting, analyzing and publicly reporting information on health care quality and cost
- Founded in 2005
- Multi-stakeholder collaborative – physicians, hospitals and health systems, health plans, employers, consumers and state government



Measure Background

- **4 new measures** related to Symptom Control During Chemotherapy (SCDC) using patient-report outcome tool
 - Symptom severity assessment using PRO-CTCAE tool (Process)
 - Symptom control – Pain severity (Outcome)
 - Symptom control – Nausea severity (Outcome)
 - Symptom control – Constipation severity (Outcome)
- Pilot-tested by oncology practices in Minnesota

Benefits of Measurement and Reporting



Steps to take now

Reporting will begin in the 2020 report year using 2019 dates of service. Here are steps to take in preparation for reporting:

- ✓ Implement the **Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE) tool** (prior to January 1, 2019)
- ✓ Download the tool and terms of use along with other resources available on MNCM's Data Portal
- ✓ Notify MNCM about plans to implement and report these measures

support@mncm.org

(612) 746-4522



Agenda

1

Data Submission Timeline

2

Denominator Identification

3

Numerator Identification

4

Validation Steps


5

Resources

6




Timelines



Submission activity	Date range
Dates of service	Jan 1, 2019 – Dec 31, 2019
Data submission	Beginning of April 2020 – Mid-May 2020*
Data validation (quality checks & audits)	April 2020 – July 2020*
Final Results	August/September 2020*

*Subject to change

Denominator



*Patients must be 18 years or older at the beginning of the index period

Value Sets

Currently found in Appendix C of the Data Collection guide

Table 1: Chemotherapy Biologic Value Set


CPT	CPT Description
96401	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic
96405	Chemotherapy administration, intralesional up to and including 7 lesions
96406	Chemotherapy administration, intralesional more than 7 lesions
96409	intravenous, push technique, single or initial substance/drug
96413	Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance/ drug
96416	Initiation of prolonged chemotherapy infusion (> 8 hours) requiring portable or implantable pump
96420	Chemotherapy administration, intra-arterial push
96422	Chemotherapy administration, intra-arterial infusion
96425	Intra-arterial pump initiation
96440	Chemo admin into pleural cavity requiring and including thoracentesis
96446	Chemotherapy administration into the peritoneal cavity via indwelling port or catheter
96450	Chemo admin into CNS requiring or including spinal puncture
96542	Chemo injection, subarachnoid or intraventricular via subcutaneous reservoir
ICD-10	ICD-10 Code Description
Z51.11	Encounter for antineoplastic chemotherapy
Z51.12	Encounter for antineoplastic immunotherapy

Remember: These should only be found using Oncology as the specialty

Note: Value Set updated October 2018



Index and Assessment Period




Index period: occurs when the patient begins a new regimen of chemotherapy and/or biologic immunotherapy and all of the following criteria are met:

- ✓ Cycle 1 Day 1 occurs between **1/1/2019 – 6/30/2019**
- ✓ Administration of chemo and/or biologic is billed by specific CPT codes (*Chemotherapy Biologic Value Set*)

Assessment period: for patients who meet the index criteria, the assessment period allows enough time for the completion of three cycles of chemotherapy for each patient by the end of the 2019 calendar year

Denominators



Note: The Portal identifies which of the additional cycles a patient is eligible for.

Denominator Example #1

An eligible patient had the following treatment regimen:

- **Cycle 1 Day 1 date:** 5/24/2019
- **Cycle 2 Day 1 date:** 6/10/2019
- **Cycle 3 Day 1 date:** [blank]

Patient did not continue treatment after finishing Cycle 2

Which of the cycle denominators would the patient be eligible for?

Cycle 1: **Yes** → Cycle 1 Day 1 occurred between 1/1/2019 - 6/30/2019 (index period)

Cycle 2: **Yes** → Cycle 2 Day 1 occurred between 1/1/2019 - 12/31/2019 (assessment period)

Cycle 3: **No** → The patient did not have a Cycle 3 Day 1 because they discontinued treatment after Cycle 2

Denominator Example #2

An eligible patient had the following treatment regimen:

- **Cycle 1 Day 1 date:** 3/31/2019
- **Cycle 2 Day 1 date:** 4/13/2019
- **Cycle 3 Day 1 date:** 5/1/2019, but discontinued treatment before end of cycle

Which of the cycle denominators would the patient be eligible for?

Cycle 1: **Yes** → Cycle 1 Day 1 occurred between 1/1/2019 - 6/30/2019 (index period)

Cycle 2: **Yes** → Cycle 2 Day 1 occurred between 1/1/2019 - 12/31/2019 (assessment period)

Cycle 3: **Yes** → Because the patient had a Cycle 3 Day 1 between 1/1/2019 – 12/31/2019 (assessment period), they would still be eligible for the measure, despite dropping out before the end of the cycle

Denominator Example #3

An eligible patient had the following treatment regimen:

- **Cycle 1 Day 1 date:** 6/29/2019
- **Cycle 2 Day 1 date:** 7/15/2019
- **Cycle 3 Day 1 date:** 8/2/2019

Which of the cycle denominators would the patient be eligible for?

Cycle 1: **Yes** → Cycle 1 Day 1 occurred between 1/1/2019 - 6/30/2019 (index period)

Cycle 2: **Yes** → Cycle 2 Day 1 occurred between 1/1/2019 - 12/31/2019 (assessment period)

Cycle 3: **Yes** → Cycle 3 Day 1 occurred between 1/1/2019 – 12/31/2019 (assessment period)

Patient Scenario #1

A 55 year old female with Stage 3 breast cancer was started on a regimen of anthracycline/cyclophosphamide chemotherapy every 21 days for 4 cycles via IV infusion as ordered by her oncologist. Her first day of her first cycle began on 2/15/19. Administration of the therapy is billed under CPT code 96413.

Should this patient be included in the denominator? **Yes**

Eligible patient criteria

- ✓ At least 18 years of age
- ✓ Receiving chemotherapy/biologic immunotherapy
- ✓ Cycle 1 Day 1 began between 1/1/2019 – 6/30/2019
- ✓ Seen by oncology specialty
- ✓ CPT/ICD10 code found in *Chemotherapy Biologic Value Set*



Patient Scenario #2

A 32 year old male with Crohn's Disease was started on a biologic treatment regimen on 7/2/2019. His gastroenterologist ordered Infliximab to be given via IV infusion every 8 weeks. Administration of the therapy is billed using CPT code 96413.


Should this patient be included in the denominator? **No**

Eligible patient criteria

- ✓ At least 18 years of age
- ✓ Receiving chemotherapy/biologic immunotherapy
- ✗ Cycle 1 Day 1 began between 1/1/2019 – 6/30/2019
- ✗ Seen by oncology specialty
- ✓ CPT/ICD10 code found in *Chemotherapy Biologic Value Set*




Measures



Measure 1: Symptom Severity Assessment

Process Measure




Interpretation: % of eligible patients for whom a symptom severity assessment was completed during Days 5 – 15 of the cycle using the PRO-CTCAE tool

*Each cycle contributes to the measure numerator (S1, S2, S3)

© 2018 MN Community Measurement. All Rights Reserved.

Measure 2: Pain

Outcome Measure Example



Interpretation: % of eligible patients whose **pain** severity was none or mild during Days 5 – 15 of the cycle

Pre-Submission

- Must be completed and approved by MNCM before data submission

See Data Submission webinar available on the MNCM Data Portal for more information

- Required information to be shown/explained in screenshots, source code and/or narrative:

- ✓ **Eligible specialty**

- What specialty?
- How is this identified?

- ✓ **Eligible patient age**

- What is the age range being used?
- How will you query this information?

- ✓ **Chemotherapy CPT/ICD10 codes**

- Which codes will be used? **List ALL codes!**

- ✓ **Index/assessment date ranges**

- What is the date range that will be used to identify patients who meet index criteria?
- What is the date range that will be used for the assessment period?



Validation

- All groups will be audited during the first report year (2020)
- 30 charts will be randomly selected for review
- Review first 8 charts
 - If no errors, audit is complete
 - If errors, additional 22 charts will be reviewed
- Passing score = 90%

For more information, please review the Data Validation webinar available in the Resources tab in the MN CM Data Portal.



Data Portal

- Home
- Group
- Clinics
- Providers
- Contacts
- Results
- REL
- Resources
- Users

Resources/Help

[Contact Support](#) | [Site Terms of Use](#) | [Data Use Agreement](#)



Frequently Asked Questions

Q: Should we include hospital-based chemotherapy administration?

A: *Similar to our other measures, the intent of the measure is to only include patients seen in an outpatient setting based on chemotherapy administration CPT codes. However, if there is an hospital-based outpatient site within your hospital (e.g. infusion center), those patients should be included.*

Q: Will MDH include this measure in the 2019 reporting rule?

A: *In general, MDH has stated that they expect no major changes to required measures for the 2019 report year. MDH is aware of this measure and MN CM will be encouraging their consideration for future inclusion.*

Contact

Questions?

support@mncm.org

612-746-4522



Connect with us!

On the web
MNCM.org
MNHealthScores.org

On social media
[@mnhealthscores](https://twitter.com/mnhealthscores)
facebook.com/mnhealthscores
[Linkedin.com/company/mn-community-measurement](https://linkedin.com/company/mn-community-measurement)

Webpages to Bookmark

- **MNCM Data Portal**
<https://data.mncm.org/login>
- **MNCM Corporate Website**
www.mncm.org
- **MNCM Consumer Website**
www.mnhealthscores.org

